Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

GlaxoSmithKline PLC (NYSE:GSK)

41.49
Delayed Data
As of Feb 23
 +0.46 / +1.12%
Today’s Change
37.20
Today|||52-Week Range
45.58
+7.74%
Year-to-Date
GSK Regular Dividend: GSK began trading ex-dividend on 02/22/17. A $0.5758 dividend will be paid to shareholders of record as of 02/24/17.
Bayer (BAYRY) Misses on Q4 Earnings; Revenues in Line
Feb 23 / Zacks.com - Paid Partner Content
3 Things Gilead Sciences' CEO Just Said That You'll Want to Know
Feb 22 / MotleyFool.com - Paid Partner Content
Top Ranked Growth Stocks to Buy for February 23rd
Feb 23 / Zacks.com - Paid Partner Content
If You Want Yield, Look to the UK
Feb 19 / GuruFocus News - Paid Partner Content
Pfizer's Leukemia Candidate Gets Priority Review in U.S.
Feb 22 / Zacks.com - Paid Partner Content
2 High-Yield Dividend Stocks That Are Ridiculously Cheap
Feb 18 / MotleyFool.com - Paid Partner Content
Gilead Sciences Raises Dividend by Double Digits
Feb 22 / GuruFocus News - Paid Partner Content
Shire (SHPG) Beats on Q4 Earnings, Sales; Gives Upbeat View
Feb 17 / Zacks.com - Paid Partner Content
Troubling Trial Data Weighed on Agenus Inc Stock Today
Feb 22 / MotleyFool.com - Paid Partner Content
Zoetis (ZTS) Beats Q4 Earnings Estimates, Lowers Outlook
Feb 16 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close41.03
Today’s open41.26
Day’s range41.16 - 41.61
Volume2,855,500
Average volume (3 months)3,964,325
Market cap$100.7B
Dividend yield6.42%
Data as of 4:02pm ET, 02/23/2017

Growth & Valuation

Earnings growth (last year)-90.48%
Earnings growth (this year)+10.00%
Earnings growth (next 5 years)+13.43%
Revenue growth (last year)+2.85%
P/E ratio370.4
Price/Sales2.52
Price/Book71.91

Competitors

 Today’s
change
Today’s
% change
ABBVAbbVie+0.58+0.95%
CELGCelgene+0.19+0.16%
BMYBristol-Myers Squibb+0.42+0.76%
AGNAllergan+0.71+0.29%
Data as of 4:01pm ET, 02/23/2017

Financials

Next reporting dateApril 26, 2017
EPS forecast (this quarter)$0.65
Annual revenue (last year)$37.5B
Annual profit (last year)$1.2B
Net profit margin3.27%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Major
Chief Executive Officer &
Executive Director
Andrew Philip Witty
Chief Financial Officer &
Executive Director
Simon Dingemans
Corporate headquarters
Brentford, Greater London

Forecasts


Search for Jobs